Effect of Bortezomib administration on autophagic cell death in colorectal cancer cells

Year 2022, Volume: 1 Issue: 1, 1 - 5, 29.04.2022

Elif Erbaş , Nevra Aydemir Celep Kader Çiftçi

Abstract

Colon cancer is the most common cancer type after breast and prostate cancer in humans. Bortezomib is a proteasome inhibitor
and is commonly preferred for the treatment of some types of cancer due to its efficiency and lower side effects. This study has
investigated the impact of Bortezomib on cell death regarding the stimulation of autophagy. Bortezomib (Velcade) was treated
to colorectal cancer cells (HT-29) for 24 hours at different concentrations (10 nM, 20 nM, and 40 nM). MTT analysis was used
to determine the viability of Bortezomib-treated HT-29 cells, and immunocytochemical methods were used to determine
bortezomib’s effects on the expression of Beclin-1 and LC3 levels in the HT-29 cells. In MTT analysis, viability was decreased
with an increase in bortezomib concentration and the lowest viability was found at 40 nM concentration. In the study, Beclin-
1 immune reactive cells were seen as higher in 10nM and 40 nM concentrations of Bortezomib than other groups. Additionally,
in LC3 evaluation, the immune reactive cell density was the highest at 40 nM concentration of Bortezomib (p<0.05). However,
the LC3 immune reactivity was higher at 20nM and 40 nM concentrations of bortezomib groups (p<0.05). The findings
revealed that the treatment of Bortezomib leads to an increase in levels of LC3 and Beclin-1 and activate the autophagy in colon
cancer cells.

Keywords

Cancer, Autophagy, Bortezomib, Beclin-1, LC3.

References

• 1